



# New Serine Protease Inhibitors with Leukotriene B<sub>4</sub> (LTB<sub>4</sub>) Receptor Binding Affinity

Yoshisuke Nakayama, Kazuhiko Senokuchi, Katsuhito Sakaki, Masashi Kato, Toru Maruyama, Toru Miyazaki, Hidenori Ito, Hisao Nakai\* and Masanori Kawamura

Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618, Japan

**Abstract**—A series of new trypsin-like serine protease inhibitors, **1**, **2** and **7–23**, containing amidinobenzene moiety was found to show potent LTB<sub>4</sub>-receptor affinity. Among them, compounds **1** and **2** were found to be LTB<sub>4</sub> receptor antagonists based on an inhibition assay of human polymorphonuclear neutrophil (PMN) intracellular calcium mobilization induced by LTB<sub>4</sub>. Compounds **1** and **2**, which satisfy the reported structural requirements for good oral activity, are expected to show a balanced dual mode of action, i.e., protease inhibitory activity and LTB<sub>4</sub> receptor antagonist activity, in vivo. © 1997 Elsevier Science Ltd.

## Introduction


Compounds containing amidine function in their molecules are known to possess a variety of biological activities such as leukotriene B<sub>4</sub> (LTB<sub>4</sub>) receptor antagonist activity,<sup>1</sup> inhibitory activity of blood coagulation factor (as illustrated in thrombin inhibitor<sup>2</sup> and fibrinogen receptor antagonist **6**<sup>3</sup>), and induced nitrogen oxide synthase inhibitor,<sup>4</sup> among others.

In the process of developing orally active trypsin-like serine protease inhibitors, we have prepared many phenyl ester derivatives with basic components such as amidine or guanidine. We screened novel serine protease inhibitors<sup>5,6</sup> including **3** and **4** to determine whether they have any additional biological activity. We found that the series of serine protease inhibitors bearing an amidinobenzene moiety possesses potent LTB<sub>4</sub> receptor binding affinity. Among them, **1** and **2** were shown to be potent LTB<sub>4</sub> antagonists when evaluated by a human polymorphonuclear neutrophil (PMN) intracellular calcium mobilization assay.<sup>7</sup> Here,


we report the synthesis and structural requirements for LTB<sub>4</sub> receptor binding affinity.

## Chemistry


Compounds **1**, **2** and **7–24** (Table 1) were prepared by the same procedure as described previously.<sup>5,6</sup> The amino ester moieties in **25–29** were synthesized as shown in Scheme 1-1 and 1-2, and compounds **25–29** were prepared as shown in Scheme 1-3. The preparation of compound **30** is shown in Scheme 2-1. Compound **31** was prepared from **65** by the sequential reactions shown in Scheme 2-2. Compounds **32**, **34a,b**, **35** and **36** were synthesized from **70a–c** and **70d,e**, respectively (Scheme 2-3). The syntheses of **69a–e** and **70a–e** are shown in Scheme 2-3. As illustrated in Scheme 2-4, **33** was synthesized from **71**. Scheme 2-5 illustrates the preparation of amidine ester derivative **37**. The preparation of **38–39** is shown in Scheme 3-1. Compounds **80a,b** were prepared from methyl-4-formylbenzoate with *t*-butyl-2-diethylphosphonopropionate




**1**: R = H  
**2**: R = Et



**3**: R = H (FOY-251)  
**4**: R = CH<sub>2</sub>CONMe<sub>2</sub> (FOY-305)



**5** (CGS25019C)



**6**

Chart 1.

**Table 1.** Effect of R<sup>1</sup> and R<sup>2</sup> on inhibition of [<sup>3</sup>H]LTB<sub>4</sub> binding to human PMN

**I**

| Compound               | R <sup>1</sup>                                       | R <sup>2</sup>                                                               | IC <sub>50</sub> (nM) <sup>a</sup> |
|------------------------|------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------|
| <b>1</b> <sup>c</sup>  | allyl                                                | CH <sub>2</sub> CO <sub>2</sub> H                                            | 201 ± 23.1                         |
| <b>2</b> <sup>c</sup>  | allyl                                                | CH <sub>2</sub> CO <sub>2</sub> Et                                           | 63 ± 7.3                           |
| <b>7</b> <sup>c</sup>  | allyl                                                | (CH <sub>2</sub> ) <sub>3</sub> CO <sub>2</sub> H                            | 126.0 ± 6.4                        |
| <b>8</b> <sup>c</sup>  | allyl                                                | (CH <sub>2</sub> ) <sub>3</sub> CO <sub>2</sub> Et                           | 27.4 ± 9.8                         |
| <b>9</b>               | allyl                                                | CH <sub>2</sub> C <sub>6</sub> H <sub>4</sub> - <i>p</i> -CO <sub>2</sub> Et | 52.7 ± 7.5                         |
| <b>10</b> <sup>c</sup> | CH <sub>2</sub> Ph                                   | CH <sub>2</sub> CO <sub>2</sub> H                                            | 23.9 ± 3.6                         |
| <b>11</b>              | Me <sub>2</sub> CH(CH <sub>2</sub> ) <sub>2</sub>    | (CH <sub>2</sub> ) <sub>2</sub> CO <sub>2</sub> Et                           | 29.2 ± 7.0                         |
| <b>12</b>              | Me <sub>2</sub> CH(CH <sub>2</sub> ) <sub>2</sub>    | CH <sub>2</sub> CO <sub>2</sub> H                                            | 25.7 ± 3.6                         |
| <b>13</b>              | <i>i</i> -Pr                                         | (CH <sub>2</sub> ) <sub>2</sub> CO <sub>2</sub> H                            | 190.1 ± 19.8                       |
| <b>14</b>              | Me                                                   | (CH <sub>2</sub> ) <sub>2</sub> CO <sub>2</sub> H                            | 3735.8 ± 294.4                     |
| <b>15</b>              | Cyclohexyl                                           | (CH <sub>2</sub> ) <sub>2</sub> CO <sub>2</sub> H                            | 25.7 ± 2.1                         |
| <b>16</b>              | (CH <sub>2</sub> ) <sub>2</sub> OMe                  | CH <sub>2</sub> CO <sub>2</sub> Et                                           | 191.4 ± 33.5                       |
| <b>17</b>              | 2-Tetrahydrofuran-yl-CH <sub>2</sub>                 | CH <sub>2</sub> CO <sub>2</sub> H                                            | 149.1 ± 39.5                       |
| <b>18</b>              | (CH <sub>2</sub> ) <sub>2</sub> CO <sub>2</sub> H    | (CH <sub>2</sub> ) <sub>2</sub> CO <sub>2</sub> H                            | >10,000 (2.8 %) <sup>b</sup>       |
| <b>19</b>              | (CH <sub>2</sub> ) <sub>2</sub> CO <sub>2</sub> Et   | CH <sub>2</sub> CO <sub>2</sub> Et                                           | 242.0 ± 6.2                        |
| <b>20</b>              | CH <sub>2</sub> CO <sub>2</sub> H                    | CH <sub>2</sub> CONH <sub>2</sub>                                            | (9.4 %) <sup>c</sup>               |
| <b>21</b>              | ( <i>E</i> )-CH <sub>2</sub> CH=CHCO <sub>2</sub> Et | CH(CH <sub>2</sub> CO <sub>2</sub> Et)CO <sub>2</sub> Et                     | 62.7 ± 16.0                        |
| <b>22</b>              | C <sub>3</sub> H <sub>7</sub>                        | CH(CH <sub>2</sub> CO <sub>2</sub> Et) <sub>2</sub>                          | 76.8 ± 14.6                        |
| <b>23</b>              | Cyclohexyl                                           | CH(CH <sub>2</sub> CO <sub>2</sub> Et) <sub>2</sub>                          | 105.0 ± 19.0                       |
| <b>24</b>              |                                                      |                                                                              | >10,000                            |

<sup>a</sup>IC<sub>50</sub> values are the mean ± SEM of three separate experiments.<sup>b</sup>Percentage of inhibition at 1 μM.<sup>c</sup>Elemental analyses of these compounds were repeated in ref 6.

and methyl-4-acetylbenzoate with *t*-butyl-2-diethylphosphonoacetate, respectively, followed by alkaline hydrolysis under the Horner–Emmons conditions. Scheme 3-2 depicts the synthesis of **40a,b** and **41a,b**. The condensation of **47b** with ethyl-3-amidinosalicylate (**82**)<sup>9</sup> gave **42** (Scheme 3-3). The preparation of **43a,b** and **44a–d** is described in Scheme 4. Unsaturated nitrile **89**, which was obtained from 6-methoxy-β-tetralone via dehydration of its cyanohydrin derivative, was converted to amidine **90**, then to **44a** by demethylation followed by salt exchange with methanesulfonic acid. The 6-amidino-7,8-dihydro-2-naphthol was converted to **44b–d** by acylation with the corresponding carboxylic acids. The synthesis of **48** is described in Scheme 5.

## Results and Discussion

The newly found synthetic serine protease inhibitors<sup>5,6</sup> were examined for LTB<sub>4</sub>-receptor binding activity. The antagonist activity of these compounds toward LTB<sub>4</sub> receptor was evaluated by their inhibition of human PMN calcium mobilization stimulated by LTB<sub>4</sub>.<sup>7</sup> Although guanidine derivatives **3** and **4** did not show any affinity toward LTB<sub>4</sub> receptor up to 10 μM, most of the newly found protease inhibitors which contain an

amidine moiety showed strong binding affinity toward the receptor at 1 μM.


As shown in Table 1, compound **24** did not show any affinity up to 10 μM. Therefore, the tail moiety R in general formulae I, II and III is thought to play an important role in the binding to the receptor. Compound **14**, possessing less lipophilic amide moiety exhibited less affinity. The introduction of carboxylic

**Table 2.** Effect of R on inhibition of [<sup>3</sup>H]LTB<sub>4</sub> binding to human PMN


**II**

| Compound  | IC <sub>50</sub> (nM) <sup>a</sup> |
|-----------|------------------------------------|
| <b>25</b> | 36.3 ± 5.2                         |
| <b>26</b> | 54.9 ± 19.2                        |
| <b>27</b> | 159.6 ± 32.7                       |
| <b>28</b> | 93.6 ± 5.7                         |
| <b>29</b> | 94.5 ± 27.4                        |


<sup>a</sup>IC<sub>50</sub> values are the mean ± SEM of three separate experiments.



Scheme 1-2




Scheme 1-3




Scheme 1. Preparation of 25–29 (General formula II)

## Scheme 2 - 1




**Reagents :** 1) *n*-BuLi, *p*-methoxybenzyl 4-formylbenzoate, THF,  $-78^{\circ}\text{C}$ , 0.5h, 67 %; 2) MsCl,  $\text{NEt}_3$ ,  $25^{\circ}\text{C}$ , 13h, 82 %; 3) TFA, anisole,  $25^{\circ}\text{C}$ , 1.5h, 63 %; 4) 4-amidinophenol hydrochloride (46), DCC, pyridine,  $25^{\circ}\text{C}$ , 17h, 95 %.

## Scheme 2 - 2




**Reagents :** 5) sodium hypophosphite,  $\text{H}_2\text{SO}_4$ , AIBN, EtOH,  $100^{\circ}\text{C}$ , 72h, 97 %; 6) EtOH, DCC, DMAP, THF,  $25^{\circ}\text{C}$ , 12h, 71 %; 7) TMSCl,  $\text{NEt}_3$ ,  $\text{CHCl}_3$ , benzyl 4-bromomethylbenzoate,  $25^{\circ}\text{C}$ , 15 days, 37 %; 8) Pd-C,  $\text{H}_2$ , EtOH,  $25^{\circ}\text{C}$ , 2h, 100 %; 9) 4-amidinophenol hydrochloride (46), DCC, pyridine,  $25^{\circ}\text{C}$ , 15h, 65 %.

## Scheme 2 - 3




**Reagents :** 10)  $\text{MeSO}_3\text{H}$ , anisole,  $25^{\circ}\text{C}$ , 2h, 46 and 73 %, respectively; 11) 1N NaOH, 1,4-dioxane,  $25^{\circ}\text{C}$ , 1h, 95, 45 and 40 %, respectively; 12) 4-amidinophenol hydrochloride (46), DCC, pyridine,  $25^{\circ}\text{C}$ , 17h, 48, 57 and 83 %, respectively; 13)  $\text{SOCl}_2$ , reflux, 0.5h; 14) 4-amidinophenol hydrochloride (46), pyridine,  $\text{CH}_2\text{Cl}_2$ ,  $5^{\circ}\text{C}$ , 2h, 37 and 50 %, respectively.

## Scheme 2 - 4



**Reagents :** 18)  $(\text{COCl})_2$ ,  $25^{\circ}\text{C}$ , 0.5h; 19) *N*-benzylpiperazine, pyridine,  $\text{CH}_2\text{Cl}_2$ ,  $5^{\circ}\text{C}$ , 2h, 86 %; 20)  $\text{MeSO}_3\text{H}$ , anisole,  $25^{\circ}\text{C}$ , 5h, 59 %; 21) 4-amidinophenol hydrochloride (46), DCC, pyridine,  $25^{\circ}\text{C}$ , 17h, 59 %.


## Scheme 2 - 5



**Reagents :** 15)  $\text{P}_2\text{S}_5$ , THF, reflux, 2.5h, 80 %; 16)  $\text{Et}_3\text{O}^+\text{BF}_4^-$ ,  $\text{CH}_2\text{Cl}_2$ ,  $25^{\circ}\text{C}$ , 0.5h; 17) *t*-butyl 4-aminomethylbenzoate,  $\text{CH}_2\text{Cl}_2$ ,  $25^{\circ}\text{C}$ , 0.5h, 39 %; 18) TFA, anisole,  $25^{\circ}\text{C}$ , 2h, 57 %; 19) 4-amidinophenol hydrochloride (46), DCC, pyridine,  $25^{\circ}\text{C}$ , 24h, 38 %.


Scheme 2. Preparation of 30–37 (general formula III).

Scheme 3 - 1




**Reagents** : 1) NaOH, 1,4-dioxane, 25 °C, 3h, 78 %; 2) ethyl *N*-allylglycinate, EDC•HCl, CH<sub>2</sub>Cl<sub>2</sub>, 25 °C, 2h, 66 %; 3) TFA, anisole, 25 °C, 2h, 100 %; 4) 4-amidinoaniline hydrochloride, DCC, pyridine, 25 °C, 12h, 21 %; 5) 4-amidinophenol hydrochloride (**46**), DCC, pyridine, 25 °C, 17h, 74 %.

Scheme 3 - 2




**Reagents** : 6) ethyl *N*-allylglycinate or L-glutamic acid diethylester hydrochloride, EDC•HCl, CH<sub>2</sub>Cl<sub>2</sub>, 25 °C, 3h, 93, 78, 85 and 80 % respectively; 7) TFA, anisole, 25 °C, 2h, 100 %; 8) 4-amidinophenol hydrochloride, DCC, pyridine, 25 °C, 15h, 61, 67, 53 and 58 %, respectively.

Scheme 3 - 3



**Reagents** : 9) DCC, pyridine, 25 °C, 17h, 54 %.





**Scheme 5.**

The introduction of ethoxycarbonyl into the 4-amidinophenol moiety (**42**) caused a reduction in receptor affinity, in comparison with **2**. The insertion of the *trans*-double bond between amidine and a phenol moiety provided **43a**, which had weaker activity than **2**. Compound **43b** is considered to have stronger activity than its corresponding *N*-alkyl derivative as a result of the increased lipophilicity of *N*-phenyl glycinate. The activity of amidinodihydronaphthalene derivatives **44a–d** was similar to that of the amidinophenol derivatives. Although compounds **44a,b** showed no affinity to the LTB<sub>4</sub> receptor up to 1 mM, compounds **44c,d**, containing an amide tail, showed moderate to potent receptor affinity. Components **1** and **2**, 4-amidinophenol **46** and carboxylic acids **47a,b** (Scheme 3-1) were inactive up to 10 mM. Interestingly, guanidine derivatives **3**, **4** and **48** did not affect the LTB<sub>4</sub> receptor. Consequently, both the conjugated amidine moiety and the lipophilic tail moiety were thought to be required for the components to show LTB<sub>4</sub> receptor affinity. Compounds **1** and **2** were found to be potent LTB<sub>4</sub> receptor antagonists when tested by the LTB<sub>4</sub>-induced human PMN intracellular calcium mobilization assay (IC<sub>50</sub> 115.0±21.0 and 106.6±33.8 nM, respectively) and degranulation assay (IC<sub>50</sub> 103.9±34.1 and 16.4±2.5 nM, respectively) (see Table 4).<sup>7</sup>

In summary, we have demonstrated that aryl amidines and vinyl amidines are a new class of LTB<sub>4</sub> receptor ligands structurally distinct from LTB<sub>4</sub> and other reported antagonists.<sup>11</sup> An amidine moiety at one end and a lipophilic moiety at the other end are necessary for the LTB<sub>4</sub> receptor affinity. The structurally closest LTB<sub>4</sub> antagonist to **1** and **2** seems to be **5** (CGS25019C).<sup>1</sup> Although these protease inhibitors were not optimized as LTB<sub>4</sub> antagonists, they are expected to show a balanced dual mode of action *in vivo*, judging from their *in vitro* potency.<sup>12</sup> In addition, compounds **1–23** may have oral activity since they satisfy the reported structural requirements for good oral activity.<sup>5,6</sup> These dually active compounds may be more useful than a protease inhibitor or LTB<sub>4</sub> antagonist alone for the treatment of inflammatory diseases, because both protease and LTB<sub>4</sub> are considered to play an important role in inflammatory diseases. Further structural modification studies of these protease inhibitors with the goal of maximization of the LTB<sub>4</sub> receptor antagonistic activity are currently underway.

## Experimental

## Chemistry

**General directions.** All  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra were obtained using a JEOL FX-90Q or Varian VXR-200s or 500s spectrometer. Mass spectra were obtained on a

**Table 4.** Inhibition of [ $^3\text{H}$ ]LTB $_4$  binding to human PMN by the miscellaneous compounds **38–48**

| Compd      | IC <sub>50</sub> (nM) <sup>a</sup> | Compd                    | IC <sub>50</sub> (nM) <sup>a</sup> |
|------------|------------------------------------|--------------------------|------------------------------------|
| <b>38</b>  | 65.0±9.8 (65.3%)                   | <b>44b</b>               | (4.3%) <sup>b</sup>                |
| <b>39</b>  | 119.2±20.7 (83.6%)                 | <b>44c</b>               | 99.1±4.9 (92.0%) <sup>b</sup>      |
| <b>40a</b> | (81.0%) <sup>b</sup>               | <b>44d</b>               | 30.6±5.2 (103.2%) <sup>b</sup>     |
| <b>40b</b> | 76.5±17.4 (89.6%) <sup>b</sup>     | <b>45a</b> <sup>10</sup> | (−6.0%) <sup>b</sup>               |
| <b>41a</b> | 50.4±20.3                          | <b>45b</b> <sup>10</sup> | (1.4%) <sup>b</sup>                |
| <b>41b</b> | 54.1±12.6                          | <b>45c</b> <sup>10</sup> | (−6.0%) <sup>b</sup>               |
| <b>42</b>  | 275.2±43.8 (78%)                   | <b>46</b>                | >10,000                            |
| <b>43a</b> | 289.1±68.3                         | <b>47a</b>               | >10,000                            |
| <b>43b</b> | 22.0±6.4                           | <b>47b</b>               | >10,000                            |
| <b>44a</b> | (3.2%) <sup>b</sup>                | <b>48</b>                | (−8.5%) <sup>b</sup>               |

<sup>a</sup>IC<sub>50</sub> values are the mean ± SEM of three separate experiments.

<sup>b</sup>Percentage of inhibition at 1 mM.

JEOL JMS-DX-303HF spectrometer. IR spectra were measured on a Perkin–Elmer FT-IR 1760X. Melting points were uncorrected. Column chromatography was carried out on silica gel (E. Merck; particle size 0.063–0.02 mm). Thin layer chromatography was performed on silica gel (Merck Art. No. 5715). All solvents were distilled before use.

**General procedure A: preparation of diethyl 2-allyl-2-[4-(4-amidinophenoxy)carbonyl]- $\alpha$ -methylcinnamamido]-malonate acetate (**29**).** This procedure illustrates the general method for the preparation of **26** and **28**. To a solution of diethyl 2-(*t*-butoxycarbonyl)aminomalonate **51** (4.0 g, 15 mmol) in DMF (30 mL) were added NaH (582 mg, 15 mmol) and allyl bromide (1.51 mL) at 0 °C, and the mixture was stirred at 25 °C for 2 h. The reaction mixture was quenched with cold water and extracted with EtOAc. The organic layer was washed with water and brine, dried over MgSO<sub>4</sub> and concentrated. Purification by column chromatography on silica gel (9% EtOAc/hexane) gave 4.50 g (98%) of **52c**: *R*<sub>f</sub> 0.53 (20% EtOAc/hexane); MS (EI, *m/e*) 315 (*M*<sup>+</sup>); <sup>1</sup>H NMR (90 MHz, CDCl<sub>3</sub>)  $\delta$  5.80 (1H, m), 5.45 (1H, m), 5.10 (2H, m), 4.20 (4H, q, *J* = 8.0 Hz), 3.00 (2H, d, *J* = 8.0 Hz), 1.40 (9H, s), 1.20 (6H, t, *J* = 8.0 Hz). A mixture of **52c** (4.50 g, 14 mmol) and 4N-HCl in EtOAc (29 mL) was stirred at 25 °C for 1 h and the reaction mixture was concentrated. Purification by column chromatography on silica gel (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) gave 3.11 g (87%) of **53c**: *R*<sub>f</sub> 0.32 (33% EtOAc/hexane); MS (EI, *m/e*) 174 (*M*<sup>+</sup>–41); <sup>1</sup>H NMR (90 MHz, CDCl<sub>3</sub>)  $\delta$  6.00 (1H, m), 5.30 (2H, m), 4.30 (4H, q, *J* = 8.0 Hz), 3.10 (2H, d, *J* = 8.0 Hz), 1.30 (6H, t, *J* = 8.0 Hz). A mixture of thionyl chloride (20 mL) and **57** (2.24 g, 7.57 mmol) were refluxed for 1 h. Thionyl chloride was removed azeotropically with benzene. A solution of the obtained residue in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added to a stirred mixture of **53c** (1.90 g, 7.57 mmol) and pyridine (1.84 mL, 22.7 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) at 0 °C. After stirring at 25 °C for 1 h, the reaction mixture was poured into 1 N HCl and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was washed with aqueous NaHCO<sub>3</sub> and brine, dried over MgSO<sub>4</sub> and concentrated to give 3.54 g (95%) of the crude product **58c**: *R*<sub>f</sub> 0.50 (33% EtOAc/hexane); MS (EI, *m/e*) 493 (*M*<sup>+</sup>), 448, 420; <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>)  $\delta$  8.05 (2H, d, *J* = 8.0 Hz), 7.50–7.30 (8H, m), 5.60 (1H, m), 5.40 (2H, s), 5.15 (2H, m), 4.30 (4H, q, *J* = 7.0 Hz), 3.20 (2H, d, *J* = 7.0 Hz), 2.10 (3H, brs), 1.30 (6H, t, *J* = 7.0 Hz). The mixture of **58c** (3.54 g, 7.18 mmol), CH<sub>3</sub>SO<sub>3</sub>H (15 mL) and anisole (30 mL) was stirred at 25 °C for 1.5 h. To the reaction mixture was added cold water, and the mixture was then extracted with EtOAc. The organic layer was washed with H<sub>2</sub>O and brine, dried over MgSO<sub>4</sub> and concentrated. Purification by column chromatography on silica gel (1% MeOH/CHCl<sub>3</sub>) gave 2.16 g (75%) of **59c**: *R*<sub>f</sub> 0.30 (hexane/EtOAc/AcOH = 12/4/1); MS (EI, *m/e*) 403 (*M*<sup>+</sup>); <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>)  $\delta$  8.10 (2H, d, *J* = 8.0 Hz), 7.45 (3H, m), 5.60 (1H, m), 5.15 (2H, m), 4.30 (4H, q, *J* = 7.0 Hz), 3.20 (2H, d, *J* = 7.0 Hz), 2.15 (3H, brs), 1.30 (6H, t, *J* = 7.0 Hz). A mixture of 4-amidinophenol hydrochloride (925 mg, 5.36 mmol), **59c** (2.16 g, 5.36 mmol) and DCC (1.66 g, 8.04 mmol) in pyridine (20 mL) was stirred at 25 °C

overnight. The resulting urea was removed by filtration and the filtrate was concentrated in vacuo. Purification by column chromatography on silica gel (CHCl<sub>3</sub>/MeOH/AcOH = 20/2/1) gave 1.65 g (53%) of **29** as a white powder: *R*<sub>f</sub> 0.50 (CHCl<sub>3</sub>/MeOH/AcOH = 10/2/1); MS (EI, *m/e*) 504 (*M*<sup>+</sup>–17); IR (KBr) 3418, 3079, 2983, 1741, 1686, 1607, 1568, 1489, 1412, 1370, 1309, 1267, 1217, 1177, 1065, 1014 cm<sup>–1</sup>; <sup>1</sup>H NMR (200 MHz, CD<sub>3</sub>OD)  $\delta$  8.20 (2H, d, *J* = 8.5 Hz), 7.90 (2H, d, *J* = 11.5 Hz), 7.60 (2H, d, *J* = 8.5 Hz), 7.55 (2H, d, *J* = 11.5 Hz), 7.35 (1H, brs), 5.70 (1H, m), 5.15 (2H, m), 4.25 (4H, q, *J* = 7.0 Hz), 3.10 (2H, d, *J* = 7.0 Hz), 2.15 (3H, s), 1.95 (3H, s), 1.25 (6H, t, *J* = 7.0 Hz); <sup>13</sup>C NMR (50 MHz, CD<sub>3</sub>OD) 170.62, 168.82, 167.89, 165.50, 156.82, 143.08, 135.15, 134.40, 132.64, 131.34, 130.90, 130.74, 129.45, 127.32, 124.08, 120.44, 63.78, 38.30, 14.53, 14.35.

**General procedure B: preparation of *N*-[4-(4-amidinophenoxy)carbonyl]- $\alpha$ -methylcinnamoyl]-3-[3-ethoxycarbonyl-2-(*E*)-allylthio]-L-alanine ethyl ester methanesulfonate (**25**).** This procedure illustrates the general method for the preparation of **27**. To a solution of **49** (4.8 g, 22 mmol) in CH<sub>3</sub>CN (50 mL) was added sodium hydride (0.98 g, 24 mmol) at 0 °C. After stirring for 0.5 h at 0 °C, ethyl-4-bromocrotonate (75% purity, 4.1 mL, 22 mmol) was added to the resulting solution at –30 °C. After stirring for an additional 0.5 h at 25 °C, the reaction mixture was poured into ice cold water and extracted with EtOAc. The organic layer was washed with brine, dried over MgSO<sub>4</sub> and concentrated. The residue was purified by silica gel chromatography (33% EtOAc/hexane) to give 4.5 g (55%) of *N*-*t*-butoxycarbonyl-S-(3-ethoxycarbonyl-2-propenyl) cysteine ethyl ester: *R*<sub>f</sub> 0.32 (33% EtOAc/hexane). To a solution of *N*-*t*-butoxycarbonyl-S-(3-ethoxycarbonyl-2-propenyl) cysteine ethyl ester (4.5 g, 12 mmol) in AcOEt (10 mL) was added 4 N HCl in AcOEt (20 mL) at 0 °C. After 1 h at 25 °C, the resulting solution was evaporated, and the residue was filtrated and washed with Et<sub>2</sub>O to yield 2.5 g (68%) of **50**: *R*<sub>f</sub> 0.13 (33% EtOAc/hexane). To a solution of **60** (2.5 g, 8.5 mmol) and **50** (2.2 g, 8.5 mmol) in pyridine was added EDC.HCl (2.8 g, 15 mmol) at 0 °C. After 2 h at 25 °C, the reaction mixture was concentrated, diluted with AcOEt, washed with 1N HCl, water and brine, dried over MgSO<sub>4</sub> and concentrated. The residue was purified by silica gel chromatography (30% EtOAc/hexane) to yield 3.7 g (87%) of **61a**: *R*<sub>f</sub> 0.40 (33% EtOAc/hexane). To a solution of **61a** (3.7 g, 7.5 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added TFA (20 mL) at 0 °C. After 3.5 h at 25 °C, the reaction mixture was evaporated, and the resulting precipitate was collected by filtration and washed with Et<sub>2</sub>O to give 2.3 g (68%) of **62a**: *R*<sub>f</sub> 0.35 (EtOAc). To a solution of **62a** (2.3 g, 5.1 mmol) and 4-amidinophenol hydrochloride (0.9 g, 5.1 mmol) in pyridine (20 mL) was added DCC (2.0 g, 10 mmol) at 25 °C. After 15 h, the resulting urea was removed by filtration and the filtrate was evaporated. The residue was purified by silica gel chromatography (CHCl<sub>3</sub>/MeOH/AcOH = 20/2/1) to give 2.2 g (68%) of **25** as a white powder: *R*<sub>f</sub> 0.69 (CHCl<sub>3</sub>/MeOH/AcOH = 10/2/1); MS (FAB, *m/e*) 568 (*M*<sup>+</sup> + 1); IR (KBr) 3366, 1738, 1649, 1607, 1535, 1490, 1415, 1370, 1318, 1270, 1207, 1061, 1045, 1015, 885, 771,



689  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (200 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  8.22 (2H, d,  $J$  = 9.0 Hz), 7.92 (2H, d,  $J$  = 9.0 Hz), 7.60 (2H, d,  $J$  = 9.0 Hz), 7.52 (2H, d,  $J$  = 9.0 Hz), 7.37 (1H, s), 6.88 (1H, ddd,  $J$  = 15.0, 7.5, 7.5 Hz), 5.98 (1H, d,  $J$  = 15.0 Hz), 4.66 (1H, dd,  $J$  = 9.0, 5.0 Hz), 4.22 (2H, q,  $J$  = 7.0 Hz), 4.18 (2H, q,  $J$  = 7.0 Hz), 3.36 (2H, d,  $J$  = 7.5 Hz), 3.08 (1H, dd,  $J$  = 14.0, 5.0 Hz), 2.88 (1H, dd,  $J$  = 14.0, 9.0 Hz), 2.15 (3H, d,  $J$  = 2.0 Hz), 1.31 (3H, t,  $J$  = 7.0 Hz), 1.27 (3H, t,  $J$  = 7.0 Hz);  $^{13}\text{C}$  NMR (50 MHz,  $\text{CD}_3\text{OD}$ ) 172.15, 172.02, 167.70, 167.53, 165.40, 156.75, 144.72, 1143.28, 135.70, 133.86, 131.25, 130.77, 130.68, 129.21, 127.12, 124.12, 124.01, 62.76, 61.60, 53.82, 39.43, 33.33, 33.03, 14.76, 14.56, 14.51.

**Diethyl-2-[4-(4-amidinophenoxy-carbonyl)- $\alpha$ -methylcinnamamido]-2-[(*E*)-3-ethoxycarbonylallyl]malonate hydrochloride (27).**  $R_f$  0.48 ( $\text{CHCl}_3/\text{MeOH}/\text{AcOH}$  = 15/2/1); MS (EI) 576 ( $\text{M}-\text{NH}_3$ ), 503, 474, 458, 429; IR (KBr) 3363, 2984, 1741, 1674, 1606, 1488, 1412, 1369, 1267, 1216, 1177, 1096, 1066, 1014, 858, 766, 712, 541  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (200 MHz,  $\text{CD}_3\text{OD}$ ) 8.24 (2H, d,  $J$  = 8.5 Hz), 7.95 (2H, d,  $J$  = 8.5 Hz), 7.62 (2H, d,  $J$  = 8.0 Hz), 7.55 (2H, d,  $J$  = 8.0 Hz), 7.35 (1H, s), 6.85 (1H, dt,  $J$  = 7.5, 15.0 Hz), 5.93 (1H, d,  $J$  = 15.0 Hz), 4.28 (4H, q,  $J$  = 7.5 Hz), 4.18 (2H, d,  $J$  = 7.5 Hz), 3.23 (2H, d,  $J$  = 7.5 Hz), 2.14 (3H, s), 1.26 (6H, t,  $J$  = 7.5 Hz), 1.23 (3H, t,  $J$  = 7.5 Hz);  $^{13}\text{C}$  NMR (50 MHz,  $\text{CD}_3\text{OD}$ ) 170.79, 168.24, 167.60, 167.21, 165.26, 156.69, 142.90, 142.76, 134.98, 134.41, 131.24 (2C), 130.79 (2C), 130.63 (2C), 129.31, 127.01, 126.55, 123.96 (2C), 117.06, 67.26, 63.95 (2C), 61.59, 36.72, 14.65, 14.58, 14.40 (2C).

**Preparation of 4-(4-amidinophenoxy-carbonyl)styrylphosphonic acid diethyl ester acetate (30).** To a solution of diethyl methyl phosphonate (14 g, 97 mmol) in THF (100 mL) was added 1.4M *n*-BuLi in hexane (60 mL) at  $-78^\circ\text{C}$ . After 0.5 h, the resulting solution was added dropwise to a solution of *p*-methoxybenzyl 4-formylbenzoate (24 g, 88 mmol) in THF (50 mL) at  $-78^\circ\text{C}$ . After 0.5 h, the reaction mixture was poured into ice cold water and extracted with EtOAc. The organic layer was washed with 1N HCl, saturated aqueous  $\text{NaHCO}_3$ , water and brine, dried over  $\text{MgSO}_4$  and concentrated. The residue was purified by silica gel chromatography (hexane/AcOEt = 1/2) to give 25 g (67%) of diethyl 2-hydroxy-2-(4-methoxybenzyloxycarbonyl)phenethyl phosphonate:  $R_f$  0.31 (EtOAc). To a solution of diethyl 2-hydroxy-2-(4-methoxybenzyloxycarbonyl)phenethyl phosphonate (25 g, 59 mmol) and  $\text{Et}_3\text{N}$  (33 mL, 238 mmol) in  $\text{CH}_2\text{Cl}_2$  (200 mL) was added methanesulfonyl chloride (6.9 mL, 89 mmol) at  $-20^\circ\text{C}$ . After 13 h at  $25^\circ\text{C}$ , the reaction mixture was poured into ice cold water and extracted with EtOAc. The organic layer was washed with water and brine, dried over  $\text{MgSO}_4$  and concentrated. The residue was purified by silica gel chromatography (hexane/AcOEt = 1/1) to give 19 g (82%) of **63**:  $R_f$  0.50 (EtOAc). To a solution of **63** (19 g, 49 mmol) in anisole (25 mL) was added trifluoroacetic acid (50 mL) at  $0^\circ\text{C}$ . After 1.5 h at  $25^\circ\text{C}$ , the resulting solution was evaporated, and the residue was solidified with  $\text{Et}_2\text{O}$  to give 8.8 g (63%) of **64**:  $R_f$  0.33 (EtOAc). To

a solution of **64** (1.7 g, 5.2 mmol) and 4-amidinophenol hydrochloride (1.0 g, 5.2 mmol) in pyridine (20 mL) was added DCC (1.6 g, 8 mmol) at  $25^\circ\text{C}$ . After 17 h, the resulting urea was removed by filtration and the filtrate was evaporated. The residue was purified by silica gel chromatography ( $\text{CHCl}_3/\text{MeOH}/\text{AcOH}$  = 20/2/1) to give 2.2 g (95%) of **30**:  $R_f$  0.60 ( $\text{CHCl}_3/\text{MeOH}/\text{AcOH}$  = 10/2/1); IR (KBr) 3209, 2990, 1749, 1678, 1609, 1571, 1490, 1414, 1263, 1227, 1176, 1061, 1016  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (200 MHz,  $\text{CD}_3\text{OD}$ ) 8.22 (2H, d,  $J$  = 9.0 Hz), 7.93 (2H, d,  $J$  = 9.0 Hz), 7.82 (2H, d,  $J$  = 9.0 Hz), 7.56 (1H, dd,  $J$  = 23.0, 18.0 Hz), 7.54 (2H, d,  $J$  = 9.0 Hz), 6.68 (1H, t,  $J$  = 18.0 Hz), 4.15 (4H, q,  $J$  = 7.0 Hz), 1.36 (6H, t,  $J$  = 7.0 Hz);  $^{13}\text{C}$  NMR (50 MHz,  $\text{CD}_3\text{OD}$ ) 167.69, 165.13, 156.59, 148.43, 141.46, 141.27, 131.73, 131.37, 131.03, 130.65, 129.23, 127.27, 123.94, 119.03, 117.51, 63.66, 16.70.

**Preparation of *p*-amidinophenyl-*p*-[ethoxy(3-phenylpropyl)phosphinoyl]methylbenzoate acetate (31).** A mixture of allylbenzene (23.6 g, 0.20 mol), sodium hypophosphite (63.6 g, 0.60 mol), AIBN (3.2 g, 0.019 mol) and conc.  $\text{H}_2\text{SO}_4$  (16 mL) in ethanol (500 mL) was stirred at  $100^\circ\text{C}$  for 3 days. The reaction mixture was evaporated, and 50% NaOH in water (250 mL) was poured into the residue. The aqueous layer was washed with ether (100 mL) and conc. HCl was added to the aqueous layer (pH 1.0). The mixture was extracted with EtOAc, washed with water and brine, dried over  $\text{MgSO}_4$  and concentrated in vacuo to give 35.8 g (97%) of 3-phenylpropylphosphinic acid:  $R_f$  0.71 (*iso*-PrOH/aq  $\text{NH}_4\text{OH}/\text{H}_2\text{O}$  = 7/2/3); MS (EI, *m/e*) 184 ( $\text{M}^+$ );  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ ) 7.35–7.10 (5H, m), 2.70 (2H, t,  $J$  = 7.0 Hz), 2.00–1.65 (4H, m). A mixture of 3-phenylpropylphosphinic acid (35.8 g, 0.19 mol), ethanol (23 mL), DCC (48 g, 0.23 mol) and DMAP (4.8 g, 0.039 mol) in THF (400 mL) was stirred at  $25^\circ\text{C}$  overnight. The reaction mixture was filtrated and the filtrate was concentrated in vacuo. The residue was purified by silica gel chromatography (EtOAc) to give 29.1 g (70.5%) of **66**: MS (EI, *m/e*) 212 ( $\text{M}^+$ );  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ ) 7.30–7.10 (5H, m), 4.10 (2H, m), 2.75 (2H, t,  $J$  = 7.0 Hz), 2.00–1.60 (4H, m), 1.35 (3H, t,  $J$  = 7.0 Hz). To a solution of **66** (1.2 g, 5.7 mmol) and  $\text{Et}_3\text{N}$  (2.4 mL, 17 mmol) in  $\text{CHCl}_3$  (30 mL) was added a solution of benzyl 4-bromomethylbenzoate (1.75 g, 5.7 mmol) and trimethylsilylchloride in  $\text{CHCl}_3$  (10 mL) and the mixture was stirred at  $25^\circ\text{C}$  for 1.5 day. Cold water was added to the reaction mixture and the mixture was extracted with EtOAc. The organic layer was washed with water and brine, dried over  $\text{MgSO}_4$  and concentrated in vacuo. The residue was purified by silica gel chromatography (25%  $\text{CH}_2\text{Cl}_2/\text{EtOAc}$ ) to give 900 mg (36%) of **67**:  $R_f$  0.41 (EtOAc); MS (EI, *m/e*) 436 ( $\text{M}^+$ ), 330;  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ ) 8.00 (2H, d,  $J$  = 8.0 Hz), 7.50–7.10 (12H, m), 5.40 (2H, s), 4.00 (2H, m), 3.15 (2H, d,  $J$  = 16.0 Hz), 2.65 (2H, t,  $J$  = 7.0 Hz), 1.90 (2H, m), 1.60 (2H, m), 1.25 (3H, t,  $J$  = 7.0 Hz). A mixture of **67** (900 mg, 2.1 mmol) and 10% Pd–C (180 mg) in EtOH (10 mL) was stirred vigorously under an atmosphere of  $\text{H}_2$  at  $25^\circ\text{C}$  for 2 h. The reaction mixture was filtrated through celite545 and concentrated to give

815 mg (100%) of **68**:  $R_f$  0.39 (10% MeOH/CHCl<sub>3</sub>); MS (EI,  $m/e$ ) 346 ( $M^+$ ); <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) 8.00 (2H, d,  $J$  = 8.0 Hz), 7.35–7.10 (7H, m), 4.00 (2H, m), 3.20 (2H, d,  $J$  = 16.0 Hz), 2.70 (2H, t,  $J$  = 7.0 Hz), 2.00–1.60 (4H, m), 1.25 (3H, t,  $J$  = 7.0 Hz). A solution of **68** (815 mg, 2.1 mmol), 4-amidinophenol hydrochloride (360 mg, 2.1 mmol) and DCC (640 mg, 3.1 mmol) in pyridine (10 mL) was stirred at 25 °C overnight. The reaction mixture was filtrated and the filtrate was concentrated. The residue was purified by silica gel chromatography (CHCl<sub>3</sub>/MeOH/AcOH = 20/2/1) to give 805 mg (65%) of **31** as a white powder:  $R_f$  0.62 (CHCl<sub>3</sub>/MeOH/AcOH = 10/2/1); MS (FAB,  $m/e$ ) 465 ( $M+1$ ), 329, 137; IR (KBr) 3059, 1741, 1685, 1608, 1572, 1542, 1489, 1454, 1418, 1266, 1216, 1176, 1065, 1034, 1018 cm<sup>-1</sup>; <sup>1</sup>H NMR (200 MHz, CD<sub>3</sub>OD) 8.10 (2H, d,  $J$  = 8.0 Hz), 7.95 (2H, d,  $J$  = 9.0 Hz), 7.55 (2H, d,  $J$  = 9.0 Hz), 7.60–7.40 (2H, m), 7.30–7.10 (3H, m), 7.20 (2H, d,  $J$  = 8.0 Hz), 4.00 (2H, m), 3.40 (2H, d,  $J$  = 24.0 Hz), 2.70 (2H, t,  $J$  = 6.5 Hz), 2.00–1.60 (4H, m), 1.30 (3H, t,  $J$  = 7.5 Hz); <sup>13</sup>C NMR (50 MHz, CD<sub>3</sub>OD) 167.75, 165.51, 156.75, 142.17, 140.22, 140.16, 131.42, 131.06, 130.65, 129.55, 129.43, 128.62, 127.12, 124.01, 117.13, 62.39, 37.38, 37.25, 36.65 (d,  $J$  = 41.7 Hz), 27.51 (d,  $J$  = 46.5 Hz), 24.65, 16.90.

**General procedure C: preparation of *N*-[4-(4-amidinophenoxy)carbonyl]benzyl]-*N*-benzylglycine ethyl ester dihydrochloride (**35**).** This procedure illustrates the general method for the preparation of **32**, **34a**, **34b** and **36**. A mixture of **69d** (2.26 g, 5.4 mmol), methanesulfonic acid (10.5 mL) and anisole (25 mL) was stirred at 25 °C for 1 h. To the reaction mixture were added cold water and Na<sub>2</sub>CO<sub>3</sub> (8.6 g), and the mixture was extracted with CHCl<sub>3</sub>. The organic layer was washed with water and brine, dried over MgSO<sub>4</sub> and concentrated. The residue was purified by silica gel chromatography (2% MeOH/CHCl<sub>3</sub>), followed by treating with 4 N HCl in dioxane (10 mL) to give 1.76 g (89%) of **70d**: MS (EI,  $m/e$ ) 327 ( $M^+$ ), 254; <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) 8.05 (2H, d,  $J$  = 8.0 Hz), 7.55 (2H, d,  $J$  = 8.0 Hz), 7.40–7.20 (5H, m), 4.20 (2H, q,  $J$  = 7.0 Hz), 3.90 (2H, s), 3.80 (2H, s), 3.30 (2H, s), 1.25 (3H, t,  $J$  = 7.0 Hz). A mixture of **70d** (1.76 g, 4.84 mmol), 4-amidinophenol hydrochloride (0.84 g, 4.8 mmol) and DCC (1.5 g, 7.3 mmol) in pyridine (20 mL) was stirred at 25 °C overnight. The reaction mixture was filtrated and concentrated. The residue was purified by silica gel chromatography (CHCl<sub>3</sub>/MeOH/AcOH = 20/2/1) to give 1.33 g (53%) of **35** as a white powder;  $R_f$  0.42 (CHCl<sub>3</sub>/MeOH/AcOH = 10/2/1); MS (EI/ $m/e$ ) 428 ( $M^+-17$ ), 355, 310, 253, 235, 192, 91; IR (KBr) 3361, 2987, 1749, 1733, 1684, 1668, 1609, 1562, 1490, 1416, 1373, 1302, 1266, 1220, 1194, 1174, 1125, 1072, 1031, 1019 cm<sup>-1</sup>; <sup>1</sup>H NMR (200 MHz, CD<sub>3</sub>OD) 8.25 (2H, d,  $J$  = 8.0 Hz), 7.90 (2H, d,  $J$  = 8.0 Hz), 7.60 (2H, d,  $J$  = 8.0 Hz), 7.50 (2H, d,  $J$  = 8.0 Hz), 7.40–7.20 (5H, m), 4.15 (2H, q,  $J$  = 7 Hz), 3.90 (2H, s), 3.80 (2H, s), 3.30 (2H, s), 1.25 (3H, t,  $J$  = 7.0 Hz); <sup>13</sup>C NMR (50 MHz, CD<sub>3</sub>OD) 172.65, 167.73, 165.69, 156.81, 147.67, 139.82, 131.24, 130.51, 130.25, 130.01, 129.34, 128.91, 128.34, 127.06, 124.02, 117.13, 61.46, 59.01, 58.58, 54.74, 14.61.

***p*-Amidinophenyl-*p*-(4-phenylpiperidinomethyl)benzoate dihydrochloride (**32**).**  $R_f$  0.33 (CHCl<sub>3</sub>/MeOH/AcOH = 5/1/1); MS (FAB,  $m/e$ ) 414 ( $M^++1$ ); IR (KBr) 3382, 2714, 1743, 1677, 1607, 1483, 1267, 1218, 1176, 1069, 1019 cm<sup>-1</sup>; <sup>1</sup>H NMR (200 MHz, CD<sub>3</sub>OD) 8.32 (2H, d,  $J$  = 8.0 Hz), 7.95 (2H, d,  $J$  = 8.8 Hz), 7.88 (2H, d,  $J$  = 8.0 Hz), 7.55 (2H, d,  $J$  = 8.8 Hz), 7.28 (5H, m), 4.52 (2H, s), 3.62 (2H, br), 3.25 (2H, br), 2.94 (1H, m), 2.12 (4H, m); <sup>13</sup>C NMR (50 MHz, CD<sub>3</sub>OD) 167.57, 165.03, 156.52, 144.74, 136.41, 133.05, 131.80, 131.59, 130.70, 129.66, 127.91, 127.62, 127.13, 123.91, 60.98, 54.18, 40.78, 31.57.

***p*-Amidinophenyl-*p*-[(2-methyl-1-imidazolyl)methyl]-benzoate dihydrochloride (**34a**).**  $R_f$  0.23 (EtOAc/AcOH/H<sub>2</sub>O = 3/1/1); MS (EI,  $m/e$ ) 334 ( $M^+$ ), 317, 215, 199, 171, 135; IR (KBr) 3397, 1739, 1678, 1609, 1528, 1484, 1419, 1267, 1217, 1178, 1072, 1017 cm<sup>-1</sup>; <sup>1</sup>H NMR (200 MHz, CD<sub>3</sub>OD) 8.25 (2H, d,  $J$  = 8.0 Hz), 7.95 (2H, d,  $J$  = 8.0 Hz), 7.60 (1H, d,  $J$  = 2.0 Hz), 7.55 (4H, d,  $J$  = 8.0 Hz), 7.52 (1H, d,  $J$  = 2.0 Hz), 5.58 (2H, s), 2.67 (3H, s); <sup>13</sup>C NMR (50 MHz, CD<sub>3</sub>OD) 167.57, 165.04, 156.56, 146.25, 141.41, 132.04 (2C), 130.68 (2C), 130.54, 129.18 (2C), 127.10, 123.92 (2C), 123.69, 119.58, 51.52, 10.96.

***p*-Amidinophenyl-*p*-[(2-phenyl-1-imidazolyl)methyl]-benzoate dimesylate (**34b**).**  $R_f$  0.30 (CHCl<sub>3</sub>/MeOH/AcOH = 50/10/1); MS (FAB,  $m/e$ ) 397 ( $M^++1$ ); IR (KBr) 3367, 1742, 1684, 1610, 1484, 1421, 1268, 1206, 1191, 1060, 1016 cm<sup>-1</sup>; <sup>1</sup>H NMR (200 MHz, CD<sub>3</sub>OD) 8.20 (2H, d,  $J$  = 8.0 Hz), 7.95 (2H, d,  $J$  = 8.0 Hz), 7.81 (1H, d,  $J$  = 2.0 Hz), 7.79 (1H, d,  $J$  = 2.0 Hz), 7.69 (5H, brs), 7.55 (2H, d,  $J$  = 8.5 Hz), 7.39 (2H, d,  $J$  = 8.5 Hz), 5.63 (2H, s), 2.72 (6H, s); <sup>13</sup>C NMR (50 MHz, CD<sub>3</sub>OD) 167.58, 165.00, 156.53, 146.93, 141.77, 133.78, 131.92 (2C), 130.77 (2C), 130.68 (2C), 130.54, 130.45, 128.90 (2C), 127.17, 125.06, 125.04, 123.91 (2C), 123.55, 121.00, 52.43, 39.49 (2C, CH<sub>3</sub>SO<sub>3</sub>H).

**Ethyl-1-[*p*-(*p*-amidinophenoxy)carbonyl]benzyl]-2-indole-carboxylate mesylate (**36**).**  $R_f$  0.48 (CHCl<sub>3</sub>/MeOH/AcOH = 10/1/1); MS (EI,  $m/e$ ) 441 ( $M^+$ ), 322; IR (KBr) 3393, 1733, 1685, 1609, 1523, 1485, 1269, 1206, 1176, 1063 cm<sup>-1</sup>; <sup>1</sup>H NMR (200 MHz, CD<sub>3</sub>OD+CDCl<sub>3</sub>) 8.05 (2H, d,  $J$  = 8.4 Hz), 7.89 (2H, d,  $J$  = 8.8 Hz), 7.71 (1H, d,  $J$  = 8.0 Hz), 7.46 (2H, d,  $J$  = 8.8 Hz), 7.40 (1H, s), 7.37–7.30 (2H, m), 7.17 (1H, d,  $J$  = 8.0 Hz), 7.16 (2H, d,  $J$  = 8.4 Hz), 5.95 (2H, s), 4.30 (2H, q,  $J$  = 7.4 Hz), 2.73 (3H, s), 1.33 (3H, t,  $J$  = 7.4 Hz); <sup>13</sup>C NMR (50 MHz, CD<sub>3</sub>OD+CDCl<sub>3</sub>) 167.44, 165.37, 163.09, 156.57, 146.69, 140.69, 131.35, 130.48, 128.61, 127.54, 127.39, 126.82, 126.49, 123.85, 123.60, 122.03, 112.24, 111.56, 61.68, 39.75, 14.61.

**Preparation of *p*-amidinophenyl-*p*-[3-(4-benzylpiperazino)-1-methyl-3-oxo-1-(*E*)-propenyl]benzoate dihydrochloride (**33**).** A mixture of **71** (4.0 g, 0.014 mol) and oxalyl chloride (5.8 mL) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was stirred at 25 °C for 30 min, and the reaction mixture was evaporated. A solution of the residue in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added to the solution of *N*-benzylpiperazine (2.4 mL, 0.014 mol) in pyridine (40 mL) at 0 °C, and the mixture was stirred at the same temperature for 2 h.

Cold water was added to the reaction mixture and the mixture was extracted with  $\text{CH}_2\text{Cl}_2$ . The organic layer was washed with water and brine, dried over  $\text{Na}_2\text{SO}_4$  and concentrated in vacuo. The residue was purified by silica gel chromatography (33% EtOAc/hexane) to give 5.3 g (86%) of **72a** as a yellow oil:  $R_f$  0.30. A solution of **72a** (5.3 g, 0.012 mmol) and methanesulfonic acid (23 mL) in anisole (50 mL) was stirred at 25 °C for 5 h. To the reaction mixture were added cold water and 5 M NaOH (90 mL) and the aqueous layer was washed with EtOAc. To the aqueous layer was added 2 M HCl (50 mL) and the mixture was extracted with 10% MeOH/ $\text{CHCl}_3$ . The organic layer was washed with brine and dried through the pad of  $\text{MgSO}_4$ . To the filtrate was added 4 M HCl in dioxane (10 mL), and the mixture was concentrated to give 2.8 g (59%) of **72b**:  $R_f$  0.22. A mixture of **72b** (2.75 g, 6.87 mmol), 4-amidinophenol (1.18 g, 6.87 mmol) and DCC (2.13 g, 13.8 mmol) in pyridine (20 mL) was stirred at 25 °C overnight. The reaction mixture was filtrated and the filtrate was evaporated. The residue was purified by silica gel chromatography (10% MeOH/ $\text{CHCl}_3$ ) followed by treating with 4 M HCl in dioxane to give **33** as a white powder:  $R_f$  0.31 (20% MeOH/ $\text{CHCl}_3$ ); MS(FAB,  $m/e$ ) 483 ( $M^+ + 1$ ); IR(KBr) 3387, 2586, 1748, 1678, 1607, 1485, 1412, 1303, 1264, 1245, 1182, 1083, 1018  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR(200MHz,  $\text{CD}_3\text{OD}$ ) 8.20 (2H, d,  $J = 8.0$  Hz), 7.95 (2H, d,  $J = 8.0$  Hz), 7.78 (2H, d,  $J = 8.0$  Hz), 7.70–7.43 (7H, m), 6.60 (1H, d,  $J = 1.0$  Hz), 4.80–4.60 (1H, m), 4.43 (2H, s), 4.40–4.18 (1H, m), 3.80–3.40 (3H, m), 3.40–3.05 (3H, m), 2.31 (3H, s);  $^{13}\text{C}$  NMR(50 MHz,  $\text{CD}_3\text{OD}$ ) 168.69, 167.63, 165.32, 156.70, 147.96, 147.40, 132.54 (2C), 131.45, 131.33, 130.68 (2C), 130.33 (2C), 129.91, 129.74, 127.64 (2C), 127.02, 123.98 (2C), 121.54 (2C), 61.54, 52.57, 52.24, 44.13, 39.32, 18.19.

**Preparation of 2-{N-[p-(p-amidinophenoxy-carbonyl)-benzyl]imino}-N-benzyl-N-methylglycine ethyl ester (37).** To a solution of **73** (33 g, 150 mmol) in THF (200 mL) was added  $\text{P}_2\text{S}_5$  at 25 °C. The reaction mixture was heated to reflux for 2.5 h. After cooling to 25 °C, the precipitate was removed by filtration and the filtrate was evaporated. The residue was purified by silica gel chromatography (20% EtOAc/hexane) to yield 29 g (80%) of **74**:  $R_f$  0.51 and 0.43 (33% EtOAc/hexane). To a solution of **74** (5.7 g, 24 mmol) in  $\text{CH}_2\text{Cl}_2$  (50 mL) was added 1M  $\text{Et}_3\text{O}^+\text{BF}_4^-$  in  $\text{CH}_2\text{Cl}_2$  (72 mL) at 0 °C. After 0.5 h at 25 °C, the resulting solution was evaporated. The residue was washed with  $\text{Et}_2\text{O}$  to yield 6.0 g of crude **75**. To a solution of **75** (6.0 g) in  $\text{CH}_2\text{Cl}_2$  (50 mL) was added dropwise a solution of *t*-butyl 4-amino-methylbenzoate (4.9 g, 24 mmol) in  $\text{CH}_2\text{Cl}_2$  (20 mL) at 0 °C. After 0.5 h at 25 °C, the reaction mixture was poured into cold water and extracted with  $\text{CH}_2\text{Cl}_2$ . The organic layer was washed with saturated aqueous  $\text{NaHCO}_3$ , water and brine, dried over  $\text{MgSO}_4$  and concentrated. The residue was purified by silica gel chromatography (20% EtOAc/hexane) to yield 3.8 g (39%) of **76a**:  $R_f$  0.46 (25% EtOAc/hexane). To a solution of **76a** (3.7 g, 9.1 mmol) in anisole (10 mL) was added TFA (20 mL) at 0 °C. After 2 h at 25 °C, the resulting solution was evaporated and the residue was

diluted with EtOAc, washed with water and brine, dried over  $\text{MgSO}_4$  and concentrated. The residue was purified by silica gel chromatography (25% hexane/EtOAc) to yield 1.8 g (57%) of **76b**:  $R_f$  0.36 (33% hexane/EtOAc). To a solution of **76b** (1.8 g, 5.2 mmol) and 4-amidinophenol hydrochloride (0.9 g, 5.2 mmol) in pyridine (20 mL) was added DCC (2.0 g, 10 mmol) at 25 °C. After 24 h, the resulting urea was removed by filtration and the filtrate was evaporated. The residue was purified by silica gel chromatography ( $\text{CHCl}_3$ :MeOH:H:AcOH = 20:2:1) to give 0.9 g (38%) of **37** as a pale ivory powder:  $R_f$  0.34 ( $\text{CHCl}_3$ /MeOH/AcOH = 10/2/1); MS (EI,  $m/e$ ) 455 ( $M^+ - 17$ ); IR (KBr) 3392, 1741, 1678, 1624, 1609, 1575, 1490, 1455, 1415, 1261, 1226, 1174, 1097, 1069, 1018  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (200 MHz,  $\text{CD}_3\text{OD}$ ) 8.12 (2H, d,  $J = 9.0$  Hz), 7.92 (2H, d,  $J = 9.0$  Hz), 7.52 (2H, d,  $J = 9.0$  Hz), 7.48 (2H, d,  $J = 9.0$  Hz), 7.27–7.35 (5H, m), 4.50 (2H, s), 4.49 (2H, s), 4.36 (2H, q,  $J = 7.0$  Hz), 2.88 (3H, s), 1.26 (3H, t,  $J = 7.0$  Hz);  $^{13}\text{C}$  NMR (50 MHz,  $\text{CD}_3\text{OD}$ ) 167.66, 165.71, 164.59, 157.53, 156.78, 149.30, 138.18, 131.04, 130.55, 130.19, 129.59, 128.81, 128.27, 127.00, 124.01, 63.06, 54.80, 35.22, 14.41.

**General procedure D: preparation of N-allyl-N-[4-(4-amidinophenoxy-carbonyl)- $\alpha$ -methylcinnamoyl]glycine ethyl ester acetate (39).** This procedure illustrates the general method for the preparation of **38–39**. A mixture of **77c** (9.9g, 34 mmol) and 1 M NaOH (37 mL, 37 mmol) in dioxane (50 mL) was stirred at 50 °C for 2 h. To the reaction mixture was added 1 N HCl (37 mL) at 0 °C, and the mixture was extracted with EtOAc. The organic layer was washed with water and brine, dried over  $\text{MgSO}_4$  and concentrated to give 7.0 g (78%) of **77d**. A solution of **77d** (3.0 g, 11 mmol), *N*-allylglycine ethyl ester (1.6 g, 11 mmol) and EDC (3.3 g, 17 mmol) was stirred at 25 °C overnight. To the reaction mixture was poured cold water and the mixture was extracted with EtOAc. The organic layer was washed with 1 N HCl, water and brine, dried over  $\text{MgSO}_4$  and concentrated. The residue was purified by silica gel chromatography (25% EtOAc/hexane including 0.5%  $\text{Et}_3\text{N}$ ) to give 2.92 g (66%) of **78b**: MS (EI,  $m/e$ ) 387 ( $M^+$ );  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ ) 7.95 (2H, m), 7.40 (2H, m), 6.65 (1H, m), 5.80 (1H, m), 5.25 (2H, m), 4.20 (2H, q,  $J = 7.0$  Hz), 4.15–4.05 (4H, m), 2.15 (3H, brs), 1.60 (9H, s), 1.25 (3H, t,  $J = 7.0$  Hz). A solution of **78b** in  $\text{CF}_3\text{CO}_2\text{H}$  (15 mL) and  $\text{CH}_2\text{Cl}_2$  was stirred at 25 °C for 1 h. The reaction mixture was concentrated and the residue was purified by silica gel chromatography (2% MeOH/ $\text{CHCl}_3$ ) to give 2.69 g (100%) of **79**: MS (EI,  $m/e$ ) 331 ( $M^+$ );  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ ) 8.00 (2H, m), 7.55 (2H, m), 6.70 (1H, m), 5.80 (1H, m), 5.30 (2H, m), 4.25 (2H, q,  $J = 7.0$  Hz), 4.20–4.00 (4H, m), 2.15 (3H, brs), 1.30 (3H, t,  $J = 7.0$  Hz). A solution of **79** (2.7 g, 8.1 mmol), 4-amidinophenol hydrochloride (1.4 g, 8.1 mmol) and DCC (2.5 g, 12 mmol) was stirred at 25 °C overnight. The resulting urea was removed by filtration and the filtrate was concentrated. The residue was purified by silica gel chromatography ( $\text{CHCl}_3$ /MeOH/AcOH = 30/3/1) to give 3.1 g (74%) of **39** as a white powder:  $R_f$  0.41 ( $\text{CHCl}_3$ /MeOH/AcOH = 10/2/1); MS (EI,  $m/e$ ) 432

( $M^+$ -17); IR (KBr) 3401, 1741, 1678, 1610, 1484, 1419, 1377, 1273, 1213, 1190, 1063, 1019  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (200 MHz,  $\text{CD}_3\text{OD}$ ) 8.15 (2H, m), 7.95 (2H, d,  $J = 8.0$  Hz), 7.80–7.60 (2H, m), 7.55 (2H, d,  $J = 8.0$  Hz), 6.75 (1H, m), 5.90 (1H, m), 5.40–5.20 (2H, m), 4.30–4.10 (6H, m), 2.15 (3H, br), 1.30 (3H, m);  $^{13}\text{C}$  NMR (50 MHz,  $\text{CD}_3\text{OD}$ ) 174.50, 173.34, 172.54, 167.88, 165.63, 156.82, 138.29, 135.93, 134.86, 133.79, 131.88, 130.76, 130.54, 130.48, 130.24, 127.31, 124.10, 62.52, 62.52, 61.76, 53.81, 31.57, 27.31, 14.54, 14.50, 14.48.

***N*-Allyl-*N*-[4-(4-amidinophenoxy carbamoyl)- $\alpha$ -methylcinnamoyl]glycine ethyl ester methanesulfonate (38).**  $R_f$  0.34 ( $\text{CHCl}_3/\text{MeOH}/\text{AcOH} = 10/2/1$ ); MS (FAB,  $m/e$ ) 449 ( $M^+ + 1$ ); IR (KBr) 3392, 1743, 1676, 1656, 1606, 1523, 1484, 1412, 1376, 1330, 1253, 1202, 1186, 1144, 1059  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (200 MHz,  $\text{CD}_3\text{OD}$ ) 8.00 (4H, m), 7.80 (2H, d,  $J = 8.0$  Hz), 7.55 (2H, d,  $J = 7.0$  Hz), 6.70 (1H, m), 5.90 (1H, m), 5.30 (2H, m), 4.30–4.10 (6H, m), 2.75 (3H, s), 2.15 (3H, brs), 1.30 (3H, m);  $^{13}\text{C}$  NMR (50 MHz,  $\text{CD}_3\text{OD}$ ) 176.17, 170.47, 168.44, 167.64, 145.81, 140.93, 135.59, 134.73, 134.34, 130.29, 130.03, 129.98, 129.01, 124.11, 121.70, 121.63, 118.75, 62.36, 54.08, 47.76, 39.46, 16.25, 14.48.

**General procedure E: preparation of *N*-[4-[2-(4-amidinophenoxy carbonyl)-1-(*E*)-propenyl]benzoyl]-L-glutamic acid diethyl ester hydrochloride (40b).** This procedure illustrates the general method for the preparation of **40a**, **41a** and **41b**. A mixture of **80a** (2.0 g, 7.6 mmol), L-glutamic acid diethylester hydrochloride (1.8 g, 7.6 mmol) and EDC (2.2 g, 11 mmol) in pyridine (15 mL) was stirred at 25 °C overnight. To the reaction mixture was added cold water and the mixture was extracted with EtOAc. The organic layer was washed with 1 N HCl, water, saturated aqueous  $\text{NaHCO}_3$  and brine, dried over  $\text{MgSO}_4$  and concentrated. The residue was purified by silica gel chromatography (2%  $\text{CH}_2\text{Cl}_2/\text{EtOAc}$  containing 0.5%  $\text{Et}_3\text{N}$ ) to give 2.7 g (78%) of **81b** *t*-butyl ester:  $R_f$  0.36 (33% EtOAc/hexane); MS (EI,  $m/e$ ) 447 ( $M^+$ ), 402;  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ ) 7.80 (2H, d,  $J = 9.0$  Hz), 7.60 (1H, brs), 7.45 (2H, d,  $J = 9.0$  Hz), 7.05 (1H, d,  $J = 7.0$  Hz), 4.80 (1H, m), 4.25 (2H, q,  $J = 7.0$  Hz), 4.10 (2H, q,  $J = 7.0$  Hz), 2.55–2.10 (4H, m), 2.05 (3H, d,  $J = 1.0$  Hz), 1.60 (9H, s), 1.30 (3H, t,  $J = 7.0$  Hz), 1.20 (3H, t,  $J = 7.0$  Hz). A solution of **81b** *t*-butyl ester (2.7 g, 5.9 mmol) in  $\text{CF}_3\text{CO}_2\text{H}$  (20 mL) and anisole (10 mL) was stirred at 25 °C for 2 h and concentrated. The resulting solid was washed with diisopropyl ether to give 2.10 g (91%) of **81b**: MS (EI,  $m/e$ ) 377 ( $M^+$ ), 332;  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ ) 7.85 (2H, d,  $J = 9.0$  Hz), 7.80 (1H, brs), 7.50 (2H, d,  $J = 9.0$  Hz), 7.15 (1H, d,  $J = 7.0$  Hz), 4.80 (1H, m), 4.25 (2H, q,  $J = 7.0$  Hz), 4.10 (2H, q,  $J = 7.0$  Hz), 2.60–2.20 (4H, m), 2.15 (3H, d,  $J = 1.0$  Hz), 1.35 (3H, t,  $J = 7.0$  Hz), 1.25 (3H, t,  $J = 7.0$  Hz). A mixture of **81b** (2.1 g, 5.4 mmol), 4-amidinophenol hydrochloride (930 mg, 5.4 mmol) and DCC (1.7 g, 8.1 mmol) in pyridine (25 mL) was stirred at 25 °C overnight. The resulting urea was removed by filtration and the filtrate was concentrated. The residue was purified by silica gel chromatography ( $\text{CHCl}_3/\text{MeOH}/\text{AcOH} = 30/3/1$ ) to give 2.0 g (67%) of

**40b** as a white powder:  $R_f$  0.46 ( $\text{CHCl}_3/\text{MeOH}/\text{AcOH} = 10/2/1$ ); MS (FAB,  $m/e$ ) 510 ( $M^+ + 1$ ), 171, 137; IR (KBr) 3266, 1733, 1678, 1640, 1608, 1541, 1488, 1447, 1411, 1376, 1299, 1213, 1176, 1083, 1017  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (200 MHz,  $\text{CD}_3\text{OD}$ ) 8.00–7.90 (5H, m), 7.65 (2H, d,  $J = 8.0$  Hz), 7.50 (2H, d,  $J = 8.0$  Hz), 4.65 (1H, dd,  $J = 4.5$ , 4.5 Hz), 4.20 (2H, q,  $J = 6.5$  Hz), 4.15 (2H, q,  $J = 6.5$  Hz), 2.50 (2H, t,  $J = 7.5$  Hz), 2.30 (1H, m), 2.25 (3H, m), 2.10 (1H, m), 1.30 (3H, t,  $J = 6.5$  Hz), 1.25 (3H, t,  $J = 6.5$  Hz);  $^{13}\text{C}$  NMR (50 MHz,  $\text{CD}_3\text{OD}$ ) 174.33, 173.07, 169.52, 167.69, 167.40, 156.97, 141.26, 141.23, 140.01, 135.12, 130.90, 130.65, 130.59, 130.05, 128.73, 126.92, 123.97, 117.07, 62.50, 61.73, 53.88, 31.59, 27.36, 14.52.

***N*-Allyl-*N*-[4-[2-(4-amidinophenoxy carbonyl)-1-(*E*)-propenyl]benzoyl]glycine ethyl ester acetate (40a).**  $R_f$  0.49 ( $\text{CHCl}_3/\text{MeOH}/\text{AcOH} = 10/2/1$ ); MS (FAB,  $m/e$ ) 450 ( $M^+ + 1$ ); IR (KBr) 3401, 1730, 1678, 1610, 1561, 1466, 1412, 1296, 1213, 1178, 1085, 1003  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (200 MHz,  $\text{CD}_3\text{OD}$ ) 7.98 (1H, s), 7.90 (2H, d,  $J = 9.0$  Hz), 7.58 (4H, m), 7.48 (2H, d,  $J = 9.0$  Hz), 5.78–5.96 (1H, m), 5.23–5.32 (2H, m), 4.22 (2H, q,  $J = 7.0$  Hz), 4.20 (2H, s), 3.98–4.03 (2H, m), 2.24 (3H, s), 1.30 (3H, t,  $J = 7.0$  Hz);  $^{13}\text{C}$  NMR (50 MHz,  $\text{CD}_3\text{OD}$ ) 174.00, 170.51, 167.89, 167.59, 157.07, 141.30, 138.72, 136.79, 134.13, 131.12, 130.66, 129.94, 128.10, 127.14, 124.05, 118.74, 62.43, 54.43, 48.20, 23.75, 14.42.

***N*-Allyl-*N*-[4-[(*E*)-2-(4-amidinophenoxy carbonyl)-1-methylvinyl]benzoyl]glycine ethyl ester acetate (41a).**  $R_f$  0.50 ( $\text{CHCl}_3/\text{MeOH}/\text{AcOH} = 10/1/1$ ); MS (EI,  $m/e$ ) 449 ( $M^+$ ), 434; IR (KBr) 3086, 1741, 1670, 1647, 1607, 1489, 1462, 1408, 1376, 1349, 1266, 1213, 1122, 1001  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (200 MHz,  $\text{CD}_3\text{OD}$ ) 7.89 (2H, d,  $J = 8.8$  Hz), 7.73 (2H, d,  $J = 8.4$  Hz), 7.56 (2H, d,  $J = 8.4$  Hz), 7.44 (2H, d,  $J = 8.8$  Hz), 6.49 (1H, s), 5.88 (1H, m), 5.35–5.20 (2H, m), 4.30–4.10 (4H, m), 4.00 (2H, m), 2.65 (3H, s), 1.93 (3H, s), 1.31 (3H, t,  $J = 7.2$  Hz);  $^{13}\text{C}$  NMR (50 MHz,  $\text{CD}_3\text{OD}$ ) 180.00, 173.95, 170.49, 167.89, 165.34, 159.99, 156.65, 144.74, 137.57, 134.11, 130.59, 128.27, 127.88, 126.97, 124.04, 118.74, 117.22, 62.43, 54.39, 48.18, 23.41, 18.36, 14.49.

***N*-[4-[(*E*)-2-(4-Amidinophenoxy carbonyl)-1-methylvinyl]benzoyl]-L-glutamic acid diethyl ester methanesulfonate (41b).**  $R_f$  0.50 ( $\text{CHCl}_3/\text{MeOH}/\text{AcOH} = 10/1/1$ ); MS (FAB,  $m/e$ ) 510 ( $M^+ + 1$ ); IR (KBr) 3289, 1737, 1685, 1640, 1607, 1585, 1210, 1122, 1045, 1017, 1000  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (500 MHz,  $\text{CD}_3\text{OD}$ ) 7.94 (2H, d,  $J = 8.0$  Hz), 7.89 (2H, d,  $J = 8.5$  Hz), 7.72 (2H, d,  $J = 8.5$  Hz), 7.44 (2H, d,  $J = 8.0$  Hz), 6.49 (1H, s), 4.64 (1H, m), 4.23 (2H, q,  $J = 7.5$  Hz), 4.14 (2H, q,  $J = 7.0$  Hz), 2.74 (3H, s), 2.66 (3H, s), 2.52 (2H, t,  $J = 7.0$  Hz), 2.32 (2H, m), 2.14 (2H, m), 1.30 (3H, t,  $J = 7.0$  Hz), 1.25 (3H, t,  $J = 7.5$  Hz);  $^{13}\text{C}$  NMR (50 MHz,  $\text{CD}_3\text{OD}$ ) 174.36, 173.06, 169.38, 167.50, 165.11, 159.90, 156.44, 145.93, 135.75, 130.44, 128.86, 127.59, 126.54, 123.85, 117.28, 62.44, 61.67, 53.74, 39.52, 31.50, 27.22, 18.44, 14.45.

**Preparation of *N*-allyl-*N*-[4-(4-amidino-2-ethoxycarbonylphenoxy carbonyl)- $\alpha$ -methylcinnamoyl]glycine ethyl ester hydrochloride (42).** A mixture of **82** (2.0 g, 8.0

mmol), **47b** (2.3 g, 8.0 mmol) and DCC (2.0 g, 9.6 mmol) in pyridine (16 mL) was stirred at 25 °C overnight. The resulting urea was removed by filtration and the filtrate was concentrated. The residue was purified by silica gel chromatography (CHCl<sub>3</sub>/MeOH/AcOH = 30/2/1), followed by treating with 4 N HCl in dioxane (3 mL) to give 2.4 g (54%) of **42** as a white powder: *R<sub>f</sub>* 0.57 (CHCl<sub>3</sub>/MeOH/AcOH = 10/2/1); MS (EI, *m/e*) 521 (M<sup>+</sup>), 504, 330, 314; IR (KBr) 3078, 1742, 1681, 1609, 1476, 1412, 1373, 1270, 1218, 1182, 1084, 1060, 1015 cm<sup>-1</sup>; <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD) 8.48 (1H, d, *J* = 2.5 Hz), 8.21 (2H, d, *J* = 8.0 Hz), 8.08 (1H, dd, *J* = 2.5, 9.0 Hz), 7.51 (1H, d, *J* = 9.0 Hz), 7.47 (2H, d, *J* = 8.0 Hz), 6.73 (1H, brs), 6.00–5.75 (1H, m), 5.40–5.20 (2H, m), 4.38–4.20 (4H, m), 4.20–4.05 (4H, m), 2.18 (3H, brs), 1.31 (3H, t, *J* = 7.5 Hz), 1.13 (3H, t, *J* = 7.5 Hz); <sup>13</sup>C NMR (50 MHz, CD<sub>3</sub>OD) 176.05, 170.50, 167.24, 165.80, 164.89, 155.87, 142.97, 136.44, 134.35, 132.80, 131.56 (2C), 130.51 (2C), 129.83, 129.13, 127.85, 126.59 (2C), 118.77 (2C), 63.06, 62.34, 54.09, 47.79, 16.31, 14.48, 14.23.

**General procedure F: preparation of *N*-allyl-*N*-{4-[4-((*E*)-2-amidinovinyl)phenoxy carbonyl]benzoyl}glycine ethyl ester acetate (**43a**).** This procedure illustrates the general method for the preparation of **43b**. A solution of **83** (3.5 g, 13 mmol) in SOCl<sub>2</sub> (20 mL) was heated to reflux for 0.5 h. After cooling at 25 °C, the reaction mixture was concentrated and the crude acid chloride was added to a solution of ethyl *N*-allylglycinate (2.0 g, 13 mmol) in pyridine (10 mL) and CH<sub>2</sub>Cl<sub>2</sub> (10 mL) at 0 °C. After 3 h at 25 °C, the reaction mixture was poured into cold water and extracted with EtOAc. The organic layer was washed with 1N HCl, water and brine, dried over MgSO<sub>4</sub> and concentrated. The residue was purified by silica gel chromatography (25% EtOAc/hexane) to give 4.5 g (85%) of **84**: *R<sub>f</sub>* 0.38 (33% EtOAc/hexane). To a solution of **84** (4.5 g, 11 mmol) in anisole (50 mL) was added dropwise methanesulfonic acid (23 mL, 355 mmol) at 0 °C. After 2 h at 25 °C, the reaction mixture was poured into cold water and extracted with EtOAc. The organic layer was washed with water and brine, dried over MgSO<sub>4</sub> and concentrated. The residue was purified by silica gel chromatography (25% EtOAc/hexane) to give 2.6 g (77%) of **85**: *R<sub>f</sub>* 0.15 (50% EtOAc/hexane). To a solution of **85** (2.6 g, 9.1 mmol) and 3-(4-hydroxyphenyl)-2-propenimidamide **88** (1.8 g, 9.1 mmol) in pyridine (20 mL) was added DCC (3.0 g, 15 mmol) at 25 °C. After 15 h, the resulting urea was removed by filtration and the filtrate was evaporated. The residue was purified by silica gel chromatography (CHCl<sub>3</sub>/MeOH/AcOH = 20/2/1) to give 1.7 g (39%) of **43a** as a white powder: *R<sub>f</sub>* 0.43 (CHCl<sub>3</sub>/MeOH/AcOH = 10/2/1); MS (EI, *m/e*) 435 (M<sup>+</sup>), 418; IR (KBr) 3372, 1741, 1685, 1646, 1509, 1466, 1418, 1376, 1265, 1206, 1169, 1073, 1003 cm<sup>-1</sup>; <sup>1</sup>H NMR (200 MHz, CD<sub>3</sub>OD) 8.24 and 8.26 (2H, d, *J* = 9.0 Hz), 7.81 (1H, d, *J* = 18.0 Hz), 7.75 (2H, d, *J* = 9.0 Hz), 7.58 and 7.66 (2H, d, *J* = 9.0 Hz), 7.37 (2H, d, *J* = 9.0 Hz), 6.73 (1H, d, *J* = 18.0 Hz), 5.77–5.96 (1H, m), 5.22–5.34 (2H, m), 4.12–4.28 (4H, m), 3.96–4.00 (2H, m), 1.20 and 1.30 (3H, t, *J* = 7.0 Hz); <sup>13</sup>C NMR (50 MHz, CD<sub>3</sub>OD) 176.49, 173.36,

170.41, 165.40, 165.16, 154.61, 144.71, 141.85, 133.90, 133.37, 132.86, 131.95, 131.48, 130.85, 128.19, 123.82, 119.07, 118.91, 115.98, 62.50, 54.32, 48.15, 14.49.

***N*-Phenyl-*N*-{4-[4-((*E*)-2-amidinovinyl)phenoxy carbonyl]benzoyl}glycine ethyl ester acetate (**43b**).** *R<sub>f</sub>* 0.45 (CHCl<sub>3</sub>/MeOH/AcOH = 10/2/1); MS (FAB, *m/e*) 472 (M<sup>+</sup>+1), 310; IR (KBr) 3369, 1741, 1682, 1645, 1596, 1511, 1494, 1418, 1384, 1265, 1204, 1168, 1073, 1019 cm<sup>-1</sup>; <sup>1</sup>H NMR (200 MHz, CD<sub>3</sub>OD) 8.00 (2H, d, *J* = 8.0 Hz), 7.80 (1H, d, *J* = 16.0 Hz), 7.75 (2H, d, *J* = 8.0 Hz), 7.50 (2H, d, *J* = 8.0 Hz), 7.35 (2H, d, *J* = 8.0 Hz), 7.30–7.20 (5H, m), 6.70 (1H, d, *J* = 16.0 Hz), 4.65 (2H, s), 4.25 (2H, q, *J* = 7.0 Hz), 1.30 (3H, t, *J* = 7.0 Hz); <sup>13</sup>C NMR (50 MHz, CD<sub>3</sub>OD) 170.36, 165.23, 165.07, 154.55, 146.18, 144.75, 144.33, 141.99, 132.72, 131.62, 131.42, 130.77, 130.68, 130.42, 130.36, 130.00, 129.84, 129.59, 128.93, 128.85, 128.75, 128.66, 123.78, 117.16, 115.83, 62.57, 53.28, 14.51.

**General procedure G: preparation of 6-amidino-7,8-dihydro-2-naphthyl-2-naphthoate methanesulfonate (**44b**).** This procedure illustrates the general method for the preparation of **44c** and **44d**. Compound **89** (21 g, 120 mmol) was dissolved in anhydrous MeOH (600 mL), and HCl gas was introduced into the solution for 1 h at –30 °C. After 17 h at 25 °C, the resulting solution was concentrated. The residue was dissolved in anhydrous MeOH (500 mL), and NH<sub>3</sub> gas was introduced into the solution for 3 h at –30 °C. After 15 h at 25 °C, the resulting solution was concentrated and the resulting solid was collected by filtration and washed with Et<sub>2</sub>O to give 28 g (100%) of **90**: *R<sub>f</sub>* 0.58 (CHCl<sub>3</sub>/MeOH/AcOH = 10/2/1). To a solution of **90** (14 g, 68 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (100 mL) was added dropwise BBr<sub>3</sub> (50 g, 200 mmol) at –78 °C. After 2 h at 25 °C, the resulting solution was poured into cold water and then evaporated. The residue was purified by silica gel chromatography (CHCl<sub>3</sub>/MeOH/AcOH = 10/2/1) to give 13 g (71%) of acetic acid salt. To a solution of the acetic acid salt (13 g, 45 mmol) in MeOH (100 mL) was added methanesulfonic acid (5.0 mL, 49 mmol) at 5 °C. After 0.5 h at 25 °C, the resulting solution was evaporated, and the residue was solidified with Et<sub>2</sub>O to give **44a** quantitatively: *R<sub>f</sub>* 0.33 (CHCl<sub>3</sub>/MeOH/AcOH = 10/2/1). To a solution of 2-naphthoic acid (1.0 g, 6.0 mmol) and **44a** (1.4 g, 5.0 mmol) in pyridine (10 mL) was added DCC (1.4 g, 7.0 mmol) at 25 °C. After 15 h, the resulting urea was removed by filtration and the filtrate was evaporated. The residue was purified by silica gel chromatography (CHCl<sub>3</sub>/MeOH/AcOH = 20/2/1) to give 1.6 g (94%) of **44b** as a white powder: *R<sub>f</sub>* 0.52 (CHCl<sub>3</sub>/MeOH/AcOH = 10/2/1); MS (FAB, *m/e*) 343 (M<sup>+</sup>+1); IR (KBr) 3349, 1735, 1665, 1629, 1574, 1509, 1429, 1330, 1267, 1212, 1154, 1130, 1090, 1076 cm<sup>-1</sup>; <sup>1</sup>H NMR (200 MHz, CD<sub>3</sub>OD) 8.79 (1H, s), 8.13 (1H, dd, *J* = 10.0, 1.0 Hz), 8.07–7.94 (3H, m), 7.62 (2H, m), 7.48 (1H, s), 7.41 (1H, d, *J* = 9.0 Hz), 7.21–7.18 (2H, m), 3.02 (2H, t, *J* = 8.0 Hz), 2.63 (2H, t, *J* = 8.0 Hz); <sup>13</sup>C NMR (50 MHz, CD<sub>3</sub>OD) 168.02, 166.35, 153.95, 139.79, 137.31, 137.08, 136.98, 133.86, 132.94, 131.30, 130.34,

129.84, 129.58, 128.85, 128.11, 127.59, 127.31, 126.05, 122.45, 121.54, 28.15, 24.07.


**6-Amidino-7,8-dihydro-2-naphthyl-*p*-(*N*-benzyl-*N*-phenyl-carbamoyl)benzoate mesylate (44c).**  $R_f$  0.57 (CHCl<sub>3</sub>/MeOH/AcOH = 10/2/1); MS (FAB,  $m/e$ ) 502 ( $M^+ + 1$ ); IR (KBr) 3356, 1737, 1673, 1641, 1594, 1572, 1496, 1455, 1408, 1330, 1298, 1264, 1226, 1196, 1151, 1074, 1019 cm<sup>-1</sup>; <sup>1</sup>H NMR (200 MHz, CD<sub>3</sub>OD) 7.98 (2H, d,  $J$  = 8.0 Hz), 7.48 (2H, d,  $J$  = 8.0 Hz), 7.43 (1H, s), 7.38 (1H, d,  $J$  = 9.0 Hz), 7.30 (5H, s), 7.16–7.09 (5H, m), 7.02–6.99 (2H, m), 5.17 (2H, s), 2.98 (2H, t,  $J$  = 8.0 Hz), 2.60 (2H, t,  $J$  = 8.0 Hz); <sup>13</sup>C NMR (50 MHz, CD<sub>3</sub>OD) 171.54, 168.00, 165.29, 153.62, 143.42, 142.62, 139.74, 138.11, 136.97, 136.88, 131.18, 130.58, 130.48, 130.39, 130.21, 129.46, 128.55, 128.51, 127.39, 122.30, 121.39, 54.63, 28.09, 24.03.

**Ethyl-[*p*-(6-amidino-7,8-dihydro-2-naphthyloxycarbonyl)-*N*-phenylbenzamido]acetate hydrochloride (44d).**  $R_f$  0.53 (CHCl<sub>3</sub>/MeOH/AcOH = 10/2/1); MS (FAB,  $m/e$ ) 498 ( $M^+ + 1$ ); IR (KBr) 3349, 1739, 1670, 1495, 1386, 1266, 1227, 1151, 1069, 1020 cm<sup>-1</sup>; <sup>1</sup>H NMR (200 MHz, CD<sub>3</sub>OD) 8.00 (2H, d,  $J$  = 8.0 Hz), 7.50 (2H, d,  $J$  = 8.0 Hz), 7.46 (1H, s), 7.40 (1H, d,  $J$  = 8.0 Hz), 7.24 (5H, s), 7.12 (1H, s), 7.10 (1H, d,  $J$  = 8.0 Hz), 4.61 (2H, s), 4.22 (2H, q,  $J$  = 8.0 Hz), 3.00 (2H, t,  $J$  = 9.0 Hz), 2.61 (2H, t,  $J$  = 9.0 Hz), 1.30 (3H, t,  $J$  = 8.0 Hz); <sup>13</sup>C NMR (50 MHz, CD<sub>3</sub>OD) 171.72, 170.28, 168.07, 165.31, 153.66, 144.28, 141.85, 139.78, 137.02, 136.92, 131.23, 131.14, 130.62, 130.55, 130.41 (2C), 129.85, 129.73, 128.87 (2C), 128.71 (2C), 122.33, 121.41, 62.56, 53.27, 28.10, 24.07, 14.57.

***p*-[[(4-Benzhydrylpiperazino)methyl]phenyl-*p*-guanidino-benzoate acetate dihydrochloride (48).** To a solution of *p*-acetoxybenzaldehyde (3.2 g, 20 mmol) and diphenylmethylpiperazine (5.5 g, 22 mmol) in MeOH (50 mL) was added NaBH<sub>3</sub>CN (1.8 g, 30 mmol) at 0 °C. After 1 h at 25 °C, the reaction mixture was poured into cold water and extracted with EtOAc. The organic layer was washed with water and brine, dried over MgSO<sub>4</sub> and concentrated. The residue was purified by silica gel chromatography (50% EtOAc/hexane) to give 2.8 g (39%) of **91**:  $R_f$  0.37 (33% EtOAc/hexane). To a solution of **91** (2.5 g, 6 mmol) and *p*-guanidinobenzoic acid (1.9 g, 9.0 mmol) in pyridine (10 mL) and DMF (10 mL) was added DCC (3.0 g, 15 mmol) at 25 °C. After 3 days, the resulting urea was removed by filtration and the filtrate was evaporated. The residue was purified by silica gel chromatography (CHCl<sub>3</sub>/MeOH/AcOH = 10/2/1) to give 1.0 g (25%) of **48** as a white powder:  $R_f$  0.51 (CHCl<sub>3</sub>/MeOH/AcOH = 10/2/1); MS (FAB,  $m/e$ ) 520 ( $M^+ + 1$ ); IR (KBr) 3446, 1733, 1673, 1637, 1604, 1572, 1513, 1453, 1268, 1206, 1171, 1077, 1018 cm<sup>-1</sup>; <sup>1</sup>H NMR (200 MHz, CD<sub>3</sub>OD) 8.22 (2H, d,  $J$  = 9.0 Hz), 7.67 (2H, d,  $J$  = 9.0 Hz), 7.46 and 7.42 (6H, m), 7.32–7.13 (8H, m), 4.43 (1H, s), 4.38 (2H, s), 3.31 (4H, br), 2.73 (4H, br); <sup>13</sup>C NMR (50 MHz, CD<sub>3</sub>OD) 165.31, 157.46, 153.42, 142.56, 141.85, 133.81, 132.87, 129.77, 128.78, 128.52, 128.20, 124.72, 123.56, 76.18, 60.52, 52.92, 49.79.

## References

- Morrissey, M. M. Japan Kokai Tokkyo Koho, **1993**, 5-239009.
- Testa, B.; Kyburz, E.; Fuhrer, W.; Giger, R., Ed. *Perspectives in Medicinal Chemistry*; Verlag Helvetica Chimica Acta: Basel, 1993; p 27.
- Ku, T. W.; Ali, F. E.; Barton, L. S.; Bean, J. W.; Bondinell, W. E.; Burgess, J. L.; Callahan, J. F.; Calvo, R. R.; Chen, L.; Eggleston, D. S.; Gleason, J. G.; Huffman, W. F.; Hwang, S. M.; Jakas, D. R.; Karash, C. B.; Keenan, P. M.; Kopple, K. D.; Miller, W. H.; Newlander, K. A.; Nichols, A.; Parker, M. F.; Peishoff, C. E.; Samanen, J. M.; Uzinskas, I.; Venslavsky, J. W., *J. Am. Chem. Soc.*, **1993**, *115*, 8861.
- Moore, W. M.; Webber, R. K.; Fok, K. F.; Jerome, G. M.; Connor, J. R.; Manning, P. T.; Wyatt, P. S.; Misko, T. P.; Tjoeng, F. S.; Currie, M. G., *J. Med. Chem.*, **1996**, *39*, 669.
- Senokuchi, K.; Nakai, H.; Nakayama, Y.; Odagaki, Y.; Sakaki, K.; Kato, M.; Maruyama, T.; Miyazaki, T.; Ito, H.; Kamiyasu, K.; Kim, S.; Kawamura, M.; Hamanaka, N., *J. Med. Chem.*, **1995**, *38*, 2521.
- Senokuchi, K.; Nakai, H.; Nakayama, Y.; Odagaki, Y.; Sakaki, K.; Kato, M.; Maruyama, T.; Miyazaki, T.; Ito, H.; Kamiyasu, K.; Kim, S.; Kawamura, M.; Hamanaka, N., *J. Med. Chem.*, **1995**, *38*, 4508.
- (a) Kishikawa, K.; Nakao, S.; Matsumoto, S.; Kondo, K.; Hamanaka, N., *Adv. in Prostaglandin, Thromboxane, and Leukotriene Research*, **1995**, *23*, 279. (b) Most of the reported amidine derivatives which showed potent LTB<sub>4</sub> receptor affinity were estimated to be LTB<sub>4</sub> antagonists based on the results obtained in **1** and **2**.
- (a) Nii, Y.; Okano, K.; Kobayashi, S.; Ohno, M., *Tetrahedron Lett.*, **1979**, *27*, 2517. (b) A single isomer was obtained. As far as its stereochemistry (*syn* or *anti*) is concerned, exact structural determination using X-ray crystallographic analysis is in progress in our laboratory.
- Sakurai, Y.; Nakayama, T.; Yaegashi, T.; Nunomura, S.; Okutome, T. Japan Kokai Tokkyo Koho, **1983**, 58-41855.
- Compounds **45a–c** were prepared by the usual procedure.



(1) DCC, pyridine, 25 °C, 24 h; (2) TFA, anisole, 2 h.

- (a) Wikel, J. H.; Sofia, M. J.; Saussy, Jr., D. L.; Bemis, K. G., *Bioorg. Med. Chem. Lett.*, **1994**, *4*, 795. (b) Daines, R. A.; Chambers, P. A.; Eggleston, D. S.; Foley, J. J.; Griswold, D. E.; Haltiwanger, R. C.; Jakas, D. R.; Kingsbury, W. D.; Martin, L. D.; Pendrak, I.; Schmidt, D. B.; Tzimas, M. N.; Sarau,

H. M., *J. Med. Chem.*, **1994**, 37, 3327. (c) Penning, T. D.; Djuric, S. W.; Miyashiro, J. M.; Yu, S.; Snyder, J. P.; Spangler, D.; Anglin, C. P.; Fretland, D. J.; Kachur, J. F.; Keith, R. H.; Tsai, B. S.; Villani-Price, D.; Walsh, R. E.; Widomski, D. L., *J. Med. Chem.*, **1995**, 38, 858.

12. All the amidine-containing protease inhibitors reported here exhibited almost the same inhibitory activities and

spectrum as described in the previous reports<sup>5,6</sup> for **1** and **2** because they contain a common amidinophenyl function as a potency- and spectrum -determining function.

13. All of the amidine derivatives and the guanidine derivatives were isolated and evaluated as their methanesulfonates.

(Received in Japan 4 September 1996; accepted 18 February 1997)